Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -79.05M | -71.90M | -91.25M | -111.66M | -116.16M |
| Total Depreciation and Amortization | 10.42M | 12.64M | 11.68M | 11.94M | 10.94M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.44M | 13.99M | 9.41M | 23.08M | 19.03M |
| Change in Net Operating Assets | -12.88M | -7.29M | -8.53M | 9.19M | -17.49M |
| Cash from Operations | -72.07M | -52.57M | -78.70M | -67.45M | -103.69M |
| Capital Expenditure | -6.61M | -9.32M | -10.84M | -7.46M | -6.21M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.00M | 10.10M | 27.86M | 21.30M | 22.08M |
| Cash from Investing | 11.39M | 775.00K | 17.01M | 13.84M | 15.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 98.51M | 56.62M | 88.52M | 13.73M | 148.96M |
| Repurchase of Common Stock | -4.18M | -445.00K | -466.00K | -504.00K | -5.64M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 94.34M | 56.17M | 88.06M | 13.23M | 143.32M |
| Foreign Exchange rate Adjustments | -213.00K | 577.00K | -680.00K | 739.00K | 508.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.44M | 4.96M | 25.69M | -39.64M | 56.00M |